BAMCO INC /NY/ - ARROWHEAD PHARMACEUTICALS IN ownership

ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 267 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is 0.63 and the average weighting 0.2%.

Quarter-by-quarter ownership
BAMCO INC /NY/ ownership history of ARROWHEAD PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$4,208,353
-24.6%
156,619
+0.1%
0.01%
-20.0%
Q2 2023$5,578,829
+67.3%
156,445
+19.1%
0.02%
+50.0%
Q1 2023$3,335,477
-48.3%
131,318
-17.5%
0.01%
-54.5%
Q4 2022$6,456,138
-42.3%
159,175
-53.0%
0.02%
-38.9%
Q3 2022$11,197,000
-6.2%
338,792
-0.0%
0.04%
-5.3%
Q2 2022$11,934,000
-70.9%
338,942
-62.0%
0.04%
-62.4%
Q1 2022$40,988,000
-37.6%
891,241
-10.1%
0.10%
-27.3%
Q4 2021$65,729,000
+4.5%
991,393
-1.6%
0.14%
-2.1%
Q3 2021$62,904,000
-25.0%
1,007,594
-0.6%
0.14%
-26.0%
Q2 2021$83,911,000
+36.9%
1,013,173
+9.6%
0.19%
+27.2%
Q1 2021$61,299,000
+20.2%
924,430
+39.1%
0.15%
+19.8%
Q4 2020$50,998,000
+218.9%
664,637
+78.9%
0.13%
+157.1%
Q3 2020$15,993,000
+42.0%
371,421
+42.5%
0.05%
+19.5%
Q2 2020$11,260,000
+255.0%
260,709
+136.5%
0.04%
+156.2%
Q1 2020$3,172,000
-36.4%
110,250
+40.3%
0.02%
-15.8%
Q4 2019$4,985,000
+6.4%
78,594
-52.7%
0.02%0.0%
Q3 2019$4,686,000
+6.6%
166,294
+0.3%
0.02%
+5.6%
Q2 2019$4,394,000
+42.9%
165,794
-1.0%
0.02%
+38.5%
Q1 2019$3,074,000
+48.4%
167,494
+0.4%
0.01%
+30.0%
Q4 2018$2,072,000166,8470.01%
Other shareholders
ARROWHEAD PHARMACEUTICALS IN shareholders Q3 2020
NameSharesValueWeighting ↓
WESTERN FINANCIAL Corp 820,346$62,945,00041.38%
Johnson & Johnson Innovation - JJDC, Inc. 3,260,869$250,206,00032.27%
Aquilo Capital Management, LLC 365,926$28,078,0005.84%
L1 Capital Pty Ltd 298,687$23,127,0004.32%
First Light Asset Management, LLC 704,449$54,052,0004.00%
ACUTA CAPITAL PARTNERS, LLC 139,000$10,665,0002.90%
Evolutionary Tree Capital Management, LLC 48,265$3,703,0002.82%
Parkman Healthcare Partners LLC 127,171$9,758,0002.50%
Capital Impact Advisors, LLC 88,183$6,766,0001.66%
Tri Locum Partners LP 56,003$4,297,0001.56%
View complete list of ARROWHEAD PHARMACEUTICALS IN shareholders